Arisaph Pharmaceuticals, Inc. is an emerging drug discovery and design biopharmaceutical company located in Boston, Massachusetts, an internationally recognized center of biotechnology. The company utilizes proprietary drug discovery platforms to develop differentiated drugs that are highly potent and act on select targets for the treatment of a variety of diseases. Such drugs are expected to produce improvements in safety, efficacy and tolerability. Arisaph currently has seven drug discovery programs to develop therapies for cancer, cardiovascular disorders and diabetes. Arisaph has successfully applied its proprietary specificity profiling and retro-inverso chiral chemistry technology platforms to synthesize several promising lead drug candidates, including a DPP IV inhibitor for type II diabetes and reverse D-4F, an orally active apo A-I mimetic peptide for the treatment of atherosclerosis. Additionally, the Company has designed and synthesized promising leads for two targets of HDL ("good") cholesterol modulation and for a validated cancer target. Through a license agreement with Tufts University, Arisaph has exclusive worldwide rights to several important issued patents in the diabetes area and to several pending patent applications covering the Company's drug discovery platforms for use in developing therapies to treat several diseases.
BioImage is a biology based life science company focused on commercializing cell based assay technologies for high content pathway analysis. BioImage's patented Redistribution® technology leads the market for cell based protein translocation assays using fluorescent protein reporters. BioImage develops and sells proprietary assays for the monitoring of protein translocations and protein interactions in living cells. These assays are sold to pharmaceutical and biotechnology companies, and to academic groups for basic research. The assays are used for pathway analysis, compound profiling, target validation, and increasingly for high throughput, high content primary screening. We also perform services for biopharmaceutical companies - both custom assay development and compound profiling and screening. The company is actively out-licensing its Redistribution® IP portfolio to biopharmaceutical companies to enable them to undertake their own high content analysis programs. We have prioritized partnerships very highly - and we are engaged in numerous collaborations with biopharmaceutical companies, as well as instrument, software and service providers. We are part of Thermo Fisher Scientific, the world leader in serving science. Thermo Fisher Scientific enables customers to make the world healthier, cleaner and safer by providing analytical instruments, equipment, reagents and consumables, software and services for research, analysis, discovery and diagnostics. With annual sales of more than $9 billion, Thermo Fisher Scientific has 30,000 employees and serves more than 350,000 customers in pharmaceutical and biotech companies, hospitals and clinical diagnostic labs, universities, research institutions and government agencies as well as environmental, industrial quality and process control settings. 1. The trademarks BioImage and Redistribution used herein are owned by Fisher BioImage ApS, Denmark; BioImage is part of Thermo Fisher Scientific.
Arbor Vita (www.arborvita.com) is a biotechnology company focused on the discovery, development, and commercialization of novel drugs and diagnostics addressing disease through a new family of targets, PDZ proteins. PDZ proteins are critical elements that organize and regulate many signaling pathways in human cells. Arbor Vita is pioneering the development of both therapeutics and diagnostics through their unique understanding of the role of PDZs in cell signaling and disease. The company is addressing major health issues including cervical cancer, stroke and cardiovascular disease as well as infectious diseases such as influenza.
Saegis is a development-stage company focused on the discovery of drugs to address behavioral disorders. Saegis has clinically evaluated three small molecule drugs and has a growing pipeline of novel treatments for central nervous system (CNS) diseases involving cognitive dysfunction. The company's focus is on Alzheimer's Disease (AD), Mild Cognitive Impairment (MCI), Cognitive Impairment Associated with Schizophrenia (CIAS), and Attention Deficit Hyperactivity Disorder (ADHD). By developing a new generation of CNS therapeutics, Saegis is committed to giving new hope to patients facing memory loss and cognition deficits associated with aging, psychiatric disorders and brain trauma. Saegis' research is focused on understanding the widely observed phenomena that many individuals age "gracefully" (i.e. maintain their intellectual sharpness and memory) while a sizable portion of the population experiences a decline in cognitive ability over time. To date, the search for drugs to effectively treat cognitive decline associated with aging has been hindered by the lack of a research approach that closely mirrors the human condition. During a four year collaboration with researchers at Johns Hopkins University, valuable preclinical data that closely mirror the complexities of cognitive decline observed in elderly humans was generated. Saegis has identified new drug development approaches and has validated the preclinical efficacy of drug candidates, thereby decreasing development risk. Saegis focuses on specific drugs that have already been tested in humans for new indications (re-purposed drugs) and that may result in overcoming conditions of cognitive impairment or decline in humans. The ultimate vision of Saegis is to present to patients the opportunity to "age gracefully" even before it may be apparent that the decline is well underway. Saegis' accomplishments to date have placed it at the lead of a relatively small group of companies positioned to address the large, emerging market opportunity in the area of memory and cognition. In 2006, Saegis expects to complete its Proof of Concept Phase II trial with SGS518 in CIAS. Additional compounds are in evaluation as clinical candidates, and pre-clinical work for compounds against a target identified from our technology is being conducted.
Montigen will discover and develop novel promising compounds for license or co-development with select pharmaceutical and biotechnology partners. The company will also utilize its proprietary technology in partnership with select partners. Our primary therapeutic focus is oncology. Montigen is keenly interested in discussing opportunities for potential strategic alliances with pharmaceutical and biotechnology companies to assist in the development and commercialization of our lead candidates.
GenPath employs powerful, proprietary genetic model systems to discover and develop drugs against essential targets critical to the origin, maintenance, and spread of malignant tumors. This novel, high-throughput in-vivo pathway technology platform enables the rapid functional prioritization of only the most relevant drug targets, thus dramatically improving the efficiency of drug discovery. In addition, when coupled with high-throughput genomics and bioinformatics, this platform is designed to enhance drug development through the identification of novel biomarkers for both exposure and efficacy endpoints to guide clinical development. Beyond oncology, GenPath's technologies are broadly applicable to other disease states, including cardiovascular, metabolic and neurodegenerative disorders.
Cleveland BioLabs, Inc. (CBL) is engaged in the discovery, development and commercialization of products for cancer treatment and protection of normal tissues from radiation and toxins. CBLI is a drug discovery and development company. CBLI’s pipeline includes products from two primary families of compounds: protectans and curaxins. As of December 31, 2007, the Company was developing protectans as drug candidates that protect healthy tissues from acute stresses such as radiation, chemotherapy and ischemia (pathologies developed as a result of blocking blood flow to a part of the body). Curaxins are being developed as anticancer agents that could act as mono-therapy drugs or in combination with other existing anticancer agents. The Company’s products in development include Protectans (CBLB502 and CBLB612612) and Curaxins (CBLC102). (Source: 10-K)
Transkaryotic Therapies, Inc. is a biopharmaceutical company primarily focused on researching, developing and commercializing treatments for rare diseases caused by protein deficiencies. Within this focus, the company markets ReplagalÆË, an enzyme replacement therapy for Fabry disease, and is developing treatments for Hunter syndrome and Gaucher disease. In addition to its focus on rare diseases, TKT intends to commercialize DynepoÆË, its Gene-Activated® erythropoietin product for anemia related to kidney disease, in the European Union. TKT was founded in 1988 and is headquartered in Cambridge, Massachusetts, with additional operations in Europe, Canada and Latin America.
Phylogica Limited is an Australia-based company that is engaged in the discovery and development of therapeutics directed at proteins and their interactions. The Company is engaged in the discovery of peptide-based drugs to treat inflammatory diseases. Phylogica’s technology is based on its collection of peptides (small parts of proteins), called phylomer peptides. These phylomer peptides are drugs, which can target and disrupt the interactions of proteins that cause a variety of diseases. Phylogica uses The Blocker Trap, its yeast-to-hybrid based tool to select the phylomer/s from its collection to block the disease causing protein and create new therapies.
At Inimex our goal is to attract the best and brightest candidates and provide them with challenging and exciting opportunities for career growth. We are committed to the personal and career development of our team members and believe strongly that our success is the direct result of teamwork and our common vision. At Inimex we are passionate about our mission. The development of new medicines that utilize the innate immune response to prevent or treat human disease. We also expect all of our employees to share in that passion and make the mission relevant to themselves through our vision of New Approaches, New Medicines. Inimex is committed to the concept of equal opportunity in employment and we afford equal employment opportunities to all persons.
Dynogen is a clinical stage biopharmaceutical company developing more effective treatments for gastrointestinal (GI) and genitourinary (GU) disorders. The Company has an advanced pipeline of clinical development programs focused on attractive and untapped markets in disease areas that severely impair a patient's quality of life, such as irritable bowel syndrome (IBS), nocturnal gastroesophageal reflux disease (NGERD) and overactive bladder (OAB). In 2007, Dynogen generated positive clinical proof of concept data for three of its development programs: Positive Phase 2a results for DDP733 as a treatment for IBS-c; Positive Phase 2a results for DDP225 as a treatment for IBS-d; Positive Phase 1b results for DDP733 as a treatment for NGERD. Dynogen's clinical pipeline also includes two GU programs: Dynogen is planning a Phase 2b study of DDP200 as a treatment for OAB. DDP225 is ready for Phase 2 development as a treatment for OAB. In building a portfolio, Dynogen is increasing its likelihood for clinical success in the development process by focusing on product candidates with known safety and pharmacokinetic profiles, determined dose ranging, and early evidence of efficacy. Two of Dynogen's compounds, DDP733 and DDP225, have already been clinically tested in more than 400 human subjects each. In these studies, both DDP733 and DDP225 were well tolerated. The GI and GU markets represent attractive opportunities for drug development. In 2005, worldwide pharmaceutical sales for the GI and GU markets were estimated at $20 billion and $5 billion respectively. Both markets include disorders affecting millions of patients with significant unmet needs. Dynogen believes that these markets are under-served in terms of prescription drug sales compared to other disorders.
Prolexys Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering small molecule drugs that act at novel therapeutic targets. The Company's therapeutic focus is on cancer and cardiovascular indications. Prolexys scientists have exploited proprietary proteomics-related techniques to rapidly and accurately identify drug candidates that interact with targets of interest. The result of targeted drug discovery work at Prolexys is a pipeline of product candidates with high value in areas of unmet medical need.
Privacy Policy | Terms and Conditions | Do Not Sell My Personal Information | Websites Directory
Copyright © 2022 kwtbox.com. All Rights Reserved. US Business Directory